Ameriprise Financial Inc Bei Gene, Ltd. Transaction History

Ameriprise Financial Inc

  • $375 Billion
  • Q4 2024

A detailed history of Ameriprise Financial Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Ameriprise Financial Inc holds 1,827 shares of BGNE stock, worth $414,199. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,827
Previous 1,819 0.44%
Holding current value
$414,199
Previous $408,000 17.4%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
BUY
$174.72 - $246.04 $1,397 - $1,968
8 Added 0.44%
1,827 $337,000
Q3 2024

Nov 14, 2024
SELL
$143.93 - $224.51 $23,316 - $36,370
-162 Reduced 8.18%
1,819 $408,000
Q2 2024

Aug 14, 2024
SELL
$129.52 - $174.32 $69,811 - $93,958
-539 Reduced 21.39%
1,981 $282,000
Q1 2024

May 15, 2024
SELL
$141.8 - $181.47 $318,482 - $407,581
-2,246 Reduced 47.13%
2,520 $394,000
Q4 2023

Feb 14, 2024
BUY
$158.67 - $201.58 $84,888 - $107,845
535 Added 12.64%
4,766 $859,000
Q3 2023

Nov 14, 2023
BUY
$179.87 - $225.13 $2,877 - $3,602
16 Added 0.38%
4,231 $761,000
Q2 2023

Aug 14, 2023
SELL
$178.3 - $266.78 $8,023 - $12,005
-45 Reduced 1.06%
4,215 $751,000
Q1 2023

May 15, 2023
SELL
$215.53 - $274.5 $521,582 - $664,290
-2,420 Reduced 36.23%
4,260 $918,000
Q4 2022

Feb 14, 2023
SELL
$125.51 - $229.3 $503,044 - $919,034
-4,008 Reduced 37.5%
6,680 $1.47 Million
Q3 2022

Nov 14, 2022
BUY
$131.8 - $202.24 $24,646 - $37,818
187 Added 1.78%
10,688 $1.46 Million
Q2 2022

Aug 15, 2022
SELL
$121.11 - $216.05 $47,717 - $85,123
-394 Reduced 3.62%
10,501 $1.68 Million
Q1 2022

May 16, 2022
SELL
$146.52 - $269.56 $10.9 Million - $20.1 Million
-74,607 Reduced 87.26%
10,895 $2 Million
Q4 2021

Feb 14, 2022
BUY
$248.56 - $389.34 $1.61 Million - $2.53 Million
6,495 Added 8.22%
85,502 $23.1 Million
Q3 2021

Nov 15, 2021
SELL
$249.6 - $403.14 $809,702 - $1.31 Million
-3,244 Reduced 3.94%
79,007 $28.7 Million
Q2 2021

Aug 16, 2021
SELL
$292.75 - $367.01 $43,912 - $55,051
-150 Reduced 0.18%
82,251 $28.2 Million
Q1 2021

May 17, 2021
SELL
$260.64 - $382.12 $1.63 Million - $2.39 Million
-6,260 Reduced 7.06%
82,401 $28.7 Million
Q4 2020

Feb 12, 2021
SELL
$221.31 - $316.61 $6.99 Million - $10 Million
-31,571 Reduced 26.26%
88,661 $22.9 Million
Q3 2020

Nov 16, 2020
SELL
$189.18 - $286.44 $6.19 Million - $9.37 Million
-32,696 Reduced 21.38%
120,232 $34.4 Million
Q2 2020

Aug 14, 2020
BUY
$123.9 - $195.41 $2.08 Million - $3.29 Million
16,816 Added 12.35%
152,928 $28.8 Million
Q1 2020

May 15, 2020
SELL
$121.84 - $173.19 $13.2 Million - $18.7 Million
-107,929 Reduced 44.23%
136,112 $16.8 Million
Q4 2019

Feb 14, 2020
SELL
$115.78 - $208.34 $16.8 Million - $30.3 Million
-145,488 Reduced 37.35%
244,041 $40.5 Million
Q3 2019

Nov 14, 2019
BUY
$120.61 - $148.29 $4.48 Million - $5.51 Million
37,184 Added 10.55%
389,529 $47.7 Million
Q2 2019

Aug 14, 2019
SELL
$113.99 - $146.86 $575,763 - $741,789
-5,051 Reduced 1.41%
352,345 $43.7 Million
Q1 2019

May 15, 2019
SELL
$122.82 - $151.83 $2.01 Million - $2.48 Million
-16,330 Reduced 4.37%
357,396 $47.2 Million
Q4 2018

Feb 14, 2019
BUY
$107.01 - $175.15 $16.8 Million - $27.4 Million
156,536 Added 72.07%
373,726 $52.4 Million
Q3 2018

Nov 14, 2018
BUY
$152.62 - $189.66 $9.72 Million - $12.1 Million
63,692 Added 41.49%
217,190 $37.5 Million
Q2 2018

Aug 14, 2018
BUY
$152.5 - $216.77 $23.2 Million - $33 Million
152,087 Added 10778.67%
153,498 $23.6 Million
Q1 2018

May 15, 2018
BUY
$97.41 - $177.22 $137,445 - $250,057
1,411 New
1,411 $237,000

Others Institutions Holding BGNE

# of Institutions
254
Shares Held
45.1M
Call Options Held
131K
Put Options Held
95.6K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email